| 免疫药物及传统药物在晚期肾癌治疗中的价值 |
| |
| 引用本文： | 乔占兵1,李泉旺1,韩苏军2,杨静哲3,陈瑞廷4,姜 敏1,孙 韬1,胡凯文1,王金万5,陶 石6. 免疫药物及传统药物在晚期肾癌治疗中的价值[J]. 现代肿瘤医学, 2015, 0(20): 2984-2987. DOI: 10.3969/j.issn.1672-4992.2015.20.31 |
| |
| 作者姓名： | 乔占兵1 李泉旺1 韩苏军2 杨静哲3 陈瑞廷4 姜 敏1 孙 韬1 胡凯文1 王金万5 陶 石6 |
| |
| 作者单位： | 1.北京中医药大学东方医院肿瘤科，北京 100078;2.中国医学科学院肿瘤医院泌尿外科，北京 100021;3.北京中医药大学东方医院泌尿外科，北京 100078;4.河南省中医院泌尿外科，河南 郑州 450002;5.中国医学科学院肿瘤医院内科，北京 100021;6.海南医学院附属医院，海南 海口 570102 |
| |
| 基金项目： | 海南省卫生厅课题（编号:琼卫2012PT-23） |
| |
| 摘 要： | 目的:对比免疫药物及传统药物在晚期肾癌治疗中的价值。方法:晚期肾癌患者120例根据随机抽签法分为治疗组与对照组各60例，所有患者都手术根除切除，对照组术后给予舒尼替尼靶向药物治疗，治疗组术后给予干扰素-α免疫药物治疗，跟踪时间有一个月。结果:两组的有效率为88.3%、66.7%，与之前做对比，治疗组效果明显好(P＜0.05)，治疗后血清CD3和CD4值比治疗前明显高(P＜0.05)，而且治疗组治疗后的血清CD3和CD4值高于对照组(P＜0.05)。治疗过程治疗组的恶心、呕吐、疲乏等症状的总体发生情况明显低于对照组(P＜0.05)，所有不良反应经对症治疗后症状消退。治疗后随访调查1年，治疗组的半年与1年生存率分别为100.0%和96.7%，对照组为91.7%和85.0%，治疗组的生存率比较高(P＜0.05)。结论:相对于传统药物治疗，免疫药物在晚期肾癌治疗中的应用能使得机体免疫功能得到部分恢复，从而提高治疗疗效，降低不良反应的发生，促进生存率的提高。
|
| 关 键 词： | 晚期肾癌 干扰素 舒尼替尼 免疫 不良反应 生存率 |
The values of immune drugs and traditional medicines in the treatment of advanced renal cell carcinoma |
| |
| Qiao Zhanbing1,Li Quanwang1,Han Sujun2,Yang Jingzhe3,Chen Ruiting4,Jiang Min1,Sun Tao1,Hu Kaiwen1,Wang Jinwan5,Tao Shi6. The values of immune drugs and traditional medicines in the treatment of advanced renal cell carcinoma[J]. Journal of Modern Oncology, 2015, 0(20): 2984-2987. DOI: 10.3969/j.issn.1672-4992.2015.20.31 |
| |
| Authors: | Qiao Zhanbing1 Li Quanwang1 Han Sujun2 Yang Jingzhe3 Chen Ruiting4 Jiang Min1 Sun Tao1 Hu Kaiwen1 Wang Jinwan5 Tao Shi6 |
| |
| Abstract: | Objective:To compare the value of immune drugs and traditional medicines in the treatment of advanced renal cell carcinoma.Methods:All 120 patients with advanced renal cell carcinoma based on randomly were equally divided into treatment group and control group.All patients had surgical resection eradication,the control group were given sunitinib targeted drug therapy,the treatment group were given interference Su -α immune therapy.Results:The response rates in the treatment group and the control group were 88.3% and 66.7% (P＜0.05).The serum CD3 and CD4 values after treatment were significantly higher than before treatment (P＜0.05),while the value of serum CD3 and CD4 treatment group after treatment were significantly higher (P＜0.05).Both groups had no serious side effects,but the overall incidence of adverse events of nausea,vomiting,fatigue,in the treatment group were significantly lower than the control group (P＜0.05).Followed-up survey after 1 year of treatment,six months and 1 year survival rate were 100.0% and 96.7% in the treatment group,91.7% and 85.0% in the control group (P＜0.05).Conclusion:Compared with traditional medications,immune drugs in the treatment of advanced renal cell carcinoma can make partial restoration of immune function,thereby improve treatment efficacy and reduce adverse reactions,and ultimately promote the improvement of survival. |
| |
| Keywords: | advanced kidney cancer interferon sunitinib immunity adverse reactions survival |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
|
